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Abstract 
Current estimates suggest 50% of glaucoma blindness worldwide is caused by primary angle-
closure glaucoma (PACG) but the causative gene is not known. We used genetic linkage and 
whole genome sequencing to identify Spermatogenesis Associated Protein 13, SPATA13 
(NM_001166271; NP_001159743, SPATA13 isoform I), also known as ASEF2 (Adenomatous 
polyposis coli-stimulated guanine nucleotide exchange factor 2), as the causal gene for PACG 
in a large seven-generation white British family showing variable expression and incomplete 
penetrance. The 9 bp deletion, c.1432_1440del; p.478_480del was present in all affected 
individuals with angle-closure disease. We show ubiquitous expression of this transcript in 
cell lines derived from human tissues and in iris, retina, retinal pigment and ciliary epithelia, 
cornea and lens. We also identified eight additional mutations in SPATA13 in a cohort of 189 
unrelated PACS/PAC/PACG samples. This gene encodes a 1277 residue protein which localises 
to the nucleus with partial co-localisation with nuclear speckles. In cells undergoing mitosis 
SPATA13 isoform I becomes part of the kinetochore complex co-localising with two 
kinetochore markers, polo like kinase 1 (PLK-1) and centrosome-associated protein E (CENP-
E). The 9 bp deletion reported in this study increases the RAC1-dependent guanine nucleotide 
exchange factors (GEF) activity. The increase in GEF activity was also observed in three other 
variants identified in this study. Taken together, our data suggest that SPATA13 is involved in 
the regulation of mitosis and the mutations dysregulate GEF activity affecting homeostasis in 
tissues where it is highly expressed, influencing PACG pathogenesis.  
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Author summary 
Glaucoma is the leading cause of irreversible blindness globally. Angle closure glaucoma 
accounts for 50 % of all glaucoma blindness impacting quality of life and burden on health 
services. A number of variations in DNA appear to influence the risk of the disease. However, 
the biological mechanism underlying this important disease remains unclear. In this paper, 
we report the identification and functional characterisation of the first gene, mutation in 
which causes primary angle closure glaucoma in a seven generation Caucasian family. We 
have identified other variants in the same gene in another family and individuals with the 
disease. This gene is involved in cell division and is highly expressed in parts of the eye affected 
by the disease. Mutations in this gene appear to affect important enzyme activity involved in 
cell division. Identification of the disease-causing role of mutations in this gene helps to 
further the understanding of glaucoma aetiology and identifies potential therapeutic targets 
for disease management. 
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Introduction 
Glaucoma is the most common cause of irreversible blindness worldwide, affecting nearly 80 
million people [1]. It is characterised by an intermittently progressive optic neuropathy, often 
culminating in loss of vision if left untreated [2]. Two main subtypes are primary open angle 
glaucoma (POAG) [3] and primary angle closure glaucoma (PACG)[2]. PACG accounts for a 
quarter of all glaucoma, but causes half of all glaucoma blindness [4]. Physical obstruction of 
the aqueous humor outflow channels and consequent elevation of pressure inside the eye, 
are hallmarks of this disease. Typically PACG occurs in eyes that are smaller than average. [5]  
 
Two PACG loci are recognized - GLC2A in a Singaporean family on 10q identified by genetic 
linkage analysis [6] and another locus mapped to the 3q27.1 region [7] using a population-
based GWAS study in Singaporean Malay, Indian and Beijing Chinese populations. However, 
no causative gene has been identified for PACG at these loci. Vithana and co-workers found a 
genome-wide significant association between PACG and three loci: rs11024102 in pleckstrin 
homology domain containing family A member 7 (PLEKHA7) on chromosome 11p, rs3753841 
in COL11A1on chromosome 1p, and rs1015213 located between PCMTD1 and ST18 on 
chromosome 8q in a mixture of Far East, Middle East, Indian and UK populations [8, 9]. The 
two single nucleotide polymorphisms (SNPs) in PLEKHA7 and COL11A1 were replicated in a 
large PACG cohort in China [10], Australia and Nepal [11]. Variants in PLEKHA7, an adherens 
junction protein, increase the risk of sudden, symptomatic pressure rises in PACG [10]. This 
protein is expressed in iris, ciliary body, and choroid [12] and has GTPase-activating protein 
(GAP) activity [13]. SNPs in other candidate genes, including HGF (hepatocyte growth factor) 
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[14], HSP70 (heat-shock protein 70) [15], MFRP (membrane type frizzled related protein) [16], 
eNOS (endothelial nitric oxide synthase) [15] and MMP9 (matrix metalloproteinase-9) [17] 
also have significant association with PACG.  
 
Next generation sequencing has renewed interest in using family data to identify causal 
gene(s) for otherwise complex disorders. It exploits information about co-segregation, thus 
helping identify potentially causal variants. Rare variants of large effect influencing the 
susceptibility to the disease are present at a higher frequency in affected than in unaffected 
individuals in families, as well as the general population. Using this strategy, we have 
identified SPATA13 as the causative gene for PACG in a large multigenerational Caucasian 
family and shown that this protein is likely to influence tissue homeostasis. 
 
Results 
Pedigree recruitment 
A seven-generation Caucasian British family (Family 1) was recruited at Moorfields Eye 
Hospital (MEH). The proband V:8 (Fig. 1; red arrow) attended with her sister V:15 and 
daughter VI:4. They gave a strong family history of glaucoma (S1 Table). Proband V:8 had 
been treated for ocular hypertension for 15 years from age 52. On examination all three, V:8, 
V:15 and VI:4, were found to have the same phenotype of plateau iris configuration (PIC, Fig. 
2A). The proband’s mother IV:11 underwent surgery for PACG. Including her mother, the 
proband had nine other aunts and uncles, i.e. ten siblings in generation IV who lived to 
adulthood, consisting of seven sisters and three brothers. Establishing a detailed pedigree 
enabled us to expand the family tree to seven generations and contact 63 members. Twelve 
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of these (including V:11, unrelated, spouse) had occluded drainage angles (primary angle-
closure suspect - PACS), PAC (Primary angle-closure disease) or PACG (see S1 Text). The family 
had lived in the East London area since at least 1812. 
 
Linkage analysis 
All family members with occluded drainage angles or PACG were selected for linkage analysis 
(see S1, S2 Text). An autosomal dominant disease transmission was observed in Family 1, with 
more affected females than males. This may be attributable due to the majority of the 
offspring of III:11 being female (seven daughters and three sons in adulthood; five out of 
seven daughters in generation IV were affected) but could also reflect the greater 
predisposition of women because of their smaller eyes. Individual VI:7 was not included in 
this analysis as her mother, V:11, not related to this family and married-in spouse of V:10, is 
affected. For similar reasons, her daughter (VII:2) was also not included as there could be 
another gene responsible for the disease, which could come through V:11. Eleven samples 
from this family (IV:32, IV:27, V:8, V:14, V:15,V:28, V:30, V:32, V:34, V:41, VI:4 highlighted in 
yellow in Fig. 1) were genotyped on the Human CytoSNP-12 (298,199 markers) on the Illumina 
platform. Superlink Online SNPv1.1 was used to investigate genetic linkage in this family 
assuming a disease allele frequency of 1%. 
An affected-only multipoint linkage analysis was performed using IV:27, V:8, V:15, V:30, V:32, 
V:34, V:41, VI:4 (S2 Table). After removal of uninformative markers, highest positive LOD 
scores was observed on chromosome 13 between rs9580111 and rs1160226 (Max LOD Score 
2.90, NPL Spair 3.80, NPL ALL 18.7). LOD scores above 1 was also observed on chromosome 5 
between rs1478449 - rs3812042 (Max LOD score 1.25, NPL Spair 1.44, NPL ALL-0.75), 
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chromosome 9 between rs10979427- rs419097 (Max LOD score 1.72, NPL Spair 1.47, NPL ALL 
1.76). On chromosome 13 these values increased to Max LOD score 3.5, NPL Spair 4.7, NPL 
ALL 34.5 when the unaffected individual IV:32, who at 94 years of age did not show any signs 
of PACG, was included (allowing for 90% penetrance in the parametric model) (Fig. 2b). 
Including another unaffected subject V:28 also gave similar results (Max LOD score 3.760913, 
NPL-Spair 4.81, NPL ALL 37.12). A proximal crossover at rs10400673 and rs2166431 at the 
distal end in individual V:8 narrowed the genetic interval to 4.1 Mbp.  
 
Whole exome and genome sequencing 
Four “clearly affected” members of this family, V:8, V:30, V:32 and VI:12 were analysed 
further with exome sequencing using SureSelect Target Enrichment System, followed by 
sequencing on a HiSeq2000 (Illumina) with 100bp paired end reads. The average ratio of reads 
alignment to reference genome was 71%. When measured at a minimum depth of 20x, 93% 
of the intended targets were covered. Initial filtration of variants (total number of variants in 
4 samples was 98,808) was performed to identify heterozygous variants (60,329) shared 
between the four affected individuals (reduced to the total number to 4,836 variants, i.e. 
1,209 candidate variants per sample), followed by selecting all the shared variants with MAF 
of <0.01. Only one variant, SPATA13 (NM_001166271, chromosome 13q) c.1432_1440del; 
p.478_480del fulfilled the filtering criteria. On Sanger sequencing it was found that this 
variant segregated in all the nine clearly affected samples. The variant was absent in 11 of the 
16 blood-related, unaffected family members and none of the spouses carried the variant. 
Results from five of the unaffected subjects were inconclusive due to poor quality of DNA. 
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Two subjects with uncertain diagnosis and three subjects with other ocular conditions also 
carried this change. (S1 Table).  
 
The 9 bp in-frame deletion in SPATA13 results in deletion of three amino acids, QSP. There 
are three repeats of QSP within this region; the mutation deleted one of them. This variant 
had a MAF of 0.0001158 in Kavier, 0.0006118 in gnomAD Exomes, and 0.0008671 in gnomAD 
genomes. We also analysed V:15, V:30, IV:27 and V:28 by whole genome sequencing on 
HiSeqX with 30x coverage as some genes showed poor coverage on WES within the linked 
region on chromosome 13. The variants in the affected (V:15, V:30, IV:27) were compared 
with the unaffected V:28. The only variant with an allele frequency of less than 0.01 that was 
shared in all affected individuals within the linked regions was SPATA13 (NM_001166271) 
c.1432_1440del; p.478_480del. 
 
Prevalence of SPATA13 mutations in unrelated patient cohort 
To identify additional variants in SPATA13, all 13 coding exons were screened by Sanger 
sequencing in a cohort of 189 unrelated patients: PACS (n=14)/PAC (n=106, 52 acute) and 
PACG (n=69, 3 acute). One patient, (5:II:2, Fig. 2C, S3 Table) with PACS carried the same 9 bp 
SPATA13 deletion (c.1432_1440del; p.478_480del) identified in Family 1 (S3 Table). Genotype 
analysis of SNPs within SPATA13 and its adjacent region show that this individual was not 
related to Family 1. The genotypes and segregation of this mutation in this family and the 
clinical details are given in S3 Text. 
 
We also identified another eight variants in SPATA13 amongst eight unrelated patients (Table 
1, Fig. 3A), seven of them were in exon 2, the largest in this gene. In our cohort the prevalence 
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of individuals with a rare SPATA13 variant was 4.8%. The MAF of all variants were less than 
0.002 in gnomAD, 1000Genomes and EXAC databases. There are two variants that were 
identified in two subjects of African ancestry, the rest were present in Caucasian subjects. 
One variant, p.R89P, is present in 1% of the African population, the other variant, p.S246T, 
was present in 1000 Genomes with a frequency of 0.00019. We did not screen a control 
African DNA panel as it was not available to us. The rest of the variants in SPATA13 were 
screened in a control cohort of 192 random European Caucasians. In this control cohort all 
the 13 exons of SPATA13 were screened by Sanger sequencing where we identified one 
subject carrying the c.C497T, p.P166L variant. This variant also had a CADD value lower than 
10 so presumably this was a rare polymorphism. This shows that the rare variants identified 
in this study are significantly enriched in our PAC/PACG cohort (S4 Text).  
 
The degree of conservation of all the variants in SPATA13 identified in this study is shown for 
all nine species (Fig. 3B). The predicted secondary structure of SPATA13 shows that the first 
800 residues at the N-terminus, where most of the variants are located, has higher percentage 
of random coil compared with the C-terminus (Fig. 3C). The 9 base pair deletion makes the N 
terminus of SPATA13 more compact when compared with the wildtype protein (compare Fig. 
3D with 3E). 
 
Expression of SPATA13 transcripts in human cell lines and eye tissues 
Multiple SPATA13 transcripts differing in their 5’ region have been reported and designated 
ASEF2a-d [18]. One of the short transcripts, ASEF2b (NM_153023), encoding a 652 amino acid 
protein (NP_694568), has been studied in detail [19-21]. This transcript also contains one of 
the nine mutations reported above. For simplicity, we will refer NP_001159743 as SP-1277 
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and NP_694568 as SP-652 based on the amino acid number they encode. We investigated the 
expression levels of these two SPATA13 transcripts by qPCR. Transcript specific primers were 
designed to detect NM_153023 (encoding SP-652) and NM_001166271 (encoding SP-1277) 
as well as total SPATA13 as shown in figure 4A. Seventeen different human cell lines derived 
from the eye (retinal pigment epithelial, RPE-1), liver (HepG2), kidney (HEK293), cervix (HeLa), 
oesophagus (TR146), fibrosarcoma (HT1080), breast (SUM159, T47D), skin (N/Tert-1, HaCaT), 
head and neck cancers (HN4, HN8, SCC4, SCC9), oral dysplasia (SVpgC2a), and those produced 
from SVpgC2a by nicotine treatment (SVFN3 and SVFN10) [22] were analysed. As shown in 
figure 4B, these transcripts were detected in all 17 cell lines. The transcripts for SP-1277 
showed highest expression in RPE-1, SVFN3 and low in SCC9 whereas the transcript for SP-
652 was highest in N/Tert-1, SCC4 and lowest in SCC9 (Fig. 4B). These results suggest that the 
two transcripts are ubiquitously expressed at varying levels in multiple cell lines derived from 
different human tissues.  
 
We also used qPCR to investigate the mRNA expression of SP-1277 and SP-652 in human iris, 
ciliary epithelium, retinal pigmented epithelium (RPE), retina, cornea and the lens (Fig. 4C). 
The transcripts for SP-652 showed highest expression in cornea and lens, whereas the 
transcripts for SP-1277 was highest in cornea and ciliary epithelium, suggesting that SP-1277 
was the predominant transcript in tissues most affected in PAC/PACG.  
 
SPATA13 antibodies characterisation and expression in the eye  
There are several commercially available antibodies which recognise SP-1277 and SP-652. To 
confirm their specificities, we cloned SP-1277, SP-652 isoforms and the first N-terminal 625 
residues of SP-1277 (SP-1277-N625) (Fig. 5A) as AcGFP fusion proteins and expressed them in 
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HT1080 cells. Protein bands of around 166kDa (SP-1277), 100kDa (SP-652 and SP-1277-N625) 
were detected with anti-AcGFP antibody (Fig. 5B). In this study we have used four different 
antibodies, two against the N- and two against the C-terminal of SP-1277 (available from 
Abcam and ThermoFisher Scientific). The N-terminal antibodies recognised SP-1277 but 
showed no reactivity with SP-652 (representative blots of Abcam antibodies are shown in Fig. 
5B). As shown in figure 5C, the Abcam C-terminal antibody recognised a band of 70kDa and 
several high molecular weight bands in the range of 80-180kDa (Fig 5C, lane 1). The N-
terminal antibody from ThermoFisher reacted with several high molecular weight bands in 
the range of 80-180kDa (Fig. 5C, lane 2) while the Abcam antibody recognised a single band 
of 180kDa (Fig. 5C, lane 3) but did not bind to the 70kDa band showing the specificity of these 
reagents. To further test the specificity of the antibody on tissue culture cells, RPE-1 cells were 
transfected with AcGFP tagged SP-1277 (AcGFP-SP-1277) and immunostained with the N-
terminal SPATA13 antibody. As shown in figure 5D there was complete co-localisation of the 
AcGFP-SP-1277 with the N-terminal antibody. Similar results were obtained when the C-
terminal SPATA13 antibody was used to identify the AcGFP-SP-1277. These results show that 
the N and C-terminal SPATA13 antibodies were able to recognise SP-1277 in western blots 
and immunostaining. In this study, the two N-terminal SPATA13 antibodies were used 
interchangeably, however, the data presented here are mostly with the Abcam antibody. 
 
To investigate whether SP-1277 protein is expressed in the eye we used the N-terminus 
antibody on murine (Fig 5E & F) and human (Fig 5G) eye sections using 
immunohistochemistry. As shown in figures 5E-G, we observed specific reactivity with both 
pigmented and non-pigmented ciliary epithelia, iris sphincter and dilator muscles, corneal 
epithelium and retinal outer nuclear, inner nuclear and ganglion cell layers.  
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SPATA13 shows nuclear and cytoplasmic localisation in RPE-1 cells 
Having established expression of SPATA13 in the eye, we investigated the cellular localisation 
of the endogenous SP-1277 isoform using the antibodies characterised in figure 5. With the 
N-terminus antibody, a predominantly grainy nuclear staining was observed in RPE-1 cells 
(Fig. 6A). The C-terminus antibody, which should recognise all the SPATA13 isoforms, also 
gave almost identical staining (Fig. 6B). Similar observations have been reported on HeLa cells 
using SPATA13 antibodies [23]. As SP-652 has been implicated in actin function [23], we 
investigated the co-localisation of SPATA13 with F-actin in RPE-1 cells. Figure 6A and 6B show 
that both the N- and C-terminal antibodies gave reactivity in the nucleus as well as in the 
cytoplasm with little co-localisation with F-actin. We also observed no co-localisation of 
SPATA13 staining with nuclear actin (Fig. 6C).  
 
To investigate the functions of each isoform individually, we transfected AcGFP-SP-1277 and 
its N-terminus 625 residues (AcGFP-SP-1277-N625) in RPE-1 cells. AcGFP-SP-1277 was primarily 
localised as globules in the nucleus with some cytoplasmic staining (Fig. 6D), which could be 
due to a single 14 residues bipartite nuclear localisation signal (NLS) 574-RTPKRRWGSGRRPR-
587 identified by NLStradamus [24] (Fig. 5A). When AcGFP-SP-1277-N625 was ectopically 
expressed in RPE-1 cells, it gave homogenous nuclear AcGFP expression (Fig. 6E). Four of the 
nine variants (S292I, S473N, 478-480d and P964L) reported here were introduced by site-
directed mutagenesis and expressed in RPE-1 cells. The nuclear localisation of these variants 
did not change when compared with the wildtype suggesting the mutations do not affect 
localisation. (S1 Fig). 
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Role of SP-1277 in mitosis 
While investigating the cellular expression of SPATA13 isoforms, we observed that some cells 
undergoing cell division showed very speckled localisation of SP-1277 in the equatorial region 
of the dividing cells. To investigate this further, we examined the localisation of SP-1277 in 
RPE-1 cells at different stages of cell division (Fig. 7). SP-1277 showed granular nuclear signal 
at interphase with a faint background cytoplasmic signal which remained visible throughout 
mitosis (Fig. 7A). Cells were co-stained with acetylated ⍺-tubulin, to mark the microtubules, 
centrosomes and spindles. At the beginning of prophase, SP-1277 coalesced into intense 
speckles within the nucleus, which condensed further and moved towards the equatorial 
region during metaphase. At anaphase, SP-1277 speckles localised specifically along the 
kinetochore. The SP-1277 signal dispersed as the daughter cells separated, with only a faint 
background signal remaining.  
 
To investigate this novel observation, we examined whether SP-1277 was colocalising with 
the kinetochore. We co-stained RPE-1 cells for SP-1277 and two kinetochore markers, polo-
like kinase 1 (PLK-1) and centrosome associated protein E (CENP-E). As shown in figure 7B, 
SP-1277 starts to co-localise with PLK-1 at the beginning of prophase and remains co-localised 
along the kinetochore complex in pro-metaphase and metaphase. At cytokinesis SP-1277 
distributes in the cytoplasm with strong staining at the midbody. Similar colocalisation of SP-
1277 was observed with CENP-E (Fig. 7C). To quantify the degree of colocalisation we selected 
RPE-1 at two different stages of mitosis, prophase (Fig 8A) and anaphase (Fig 8F). Visual 
methods (described in S5 Text) indicated colocalisation of SP-1277 (green) and CENP-E (red) 
at prophase as shown in Fig. 8A and in Figs. 8B and 8C. We also observed that the 
colocalisation showed strong linear distribution in the scatterplots (Figs. 8D and 8E). 
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Automatic thresholding algorithm of Costes [25] showed localisation of CENP-E was 84% with 
SP-1277 and 75% of SP1277 localised with CENP-E. Similar results were obtained with ImageJ 
colocalisation plugins and the image analysis software package Imaris (Fig. 8D & 8E). At 
anaphase SP-1277 and CENP-E showed 84% colocalisation (Fig. 8F), with more colocalisation 
at the kinetochores of the separating chromosome and very little at the metaphase plate. 
 
Influence of mutations on the GEF activity of SP-1277 
As SP-652 has been shown to have GEF activity, we investigated if additional 625 residues at 
the N-terminus of SP-652 would affect this activity. GEF activity was measured by co-
transfecting AcGFP-SP-1277 (wildtype or mutants) and RAC-1 in RPE-1 cells (Fig. 9). In these 
experiments, SP-652 lacking the first 204 residues (SP-652del204) was used as positive control 
as it has been shown that removing 204 residues from the N-terminus increases its GEF 
activity [26]. There was a 1.5 fold increase in GEF activity of SP-652 compared with RAC-1 
only, which increased to 2.5 fold when the first 204 residues were deleted.  
 
SP-1277 had lower GEF activity than SP-652 (Fig. 9) suggesting the random coil region in SP-
1277 had a negative impact on its GEF activity. We also investigated whether the 9 bp deletion 
affected the GEF activity of SP-1277. There was more than 2 fold increase in GEF activity due 
to the 9 bp deletion. We further investigated the GEF activity in another three of the nine 
variants (S292I, S473N, P964L). The highest change was observed in S473N and P964L. The 
activity of SP-652 containing P964L mutation was also increased by about 2.5 fold suggesting 
that this mutation clearly affected the GEF activity.  
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Discussion 
Pathogenesis of angle closure glaucoma is complex with multiple heritable factors affecting 
the disease progression and severity. Singling out individual factors contributing to the 
disease is crucial for unravelling the pathway leading to the development of PACG. The lack 
of suitably large families with multiple affected individuals, together with disease 
heterogeneity, has hampered classical genetic linkage analyses and positional mapping 
studies of PACG. However, recent advances in medical imaging techniques, such as anterior 
segment optical coherence tomography (AS-OCT) have improved phenotypic classification of 
the angle-closure disease. We used this technique to supplement clinical examination of the 
relationship between the angle and iris and lens.  
 
In this study, we have used detailed phenotyping in combination with linkage analysis of the 
largest reported PACG family and next generation sequencing to identify SPATA13/ASEF2 as 
a gene that harbors a disease-causing mutation leading to PACG. In this family PACG was 
associated with a 9 bp deletion in SPATA13 showing variable expression and reduced 
penetrance (S6 text). There were 39 blood related subjects that were clinically examined and 
genotyped, of these 5 were unaffected, giving us a reduced penetrance of 87.2%. However, 
of the 5 unaffected, 2 males, VI:25 (42y) and VI:26 (48y), may develop PAC/PACG later, so 
excluding them from the analysis would increase the penetrance to 92.3%. There is a 
possibility, although very small, that there might be another variant deep in the intron or in 
another gene in linkage disequilibrium with SPATA13 as the filtration of variants were 
prioritised for coding regions. However, we identified additional 8 individuals with rare 
variants in SPATA13, one of whom carried the same 9 bp deletion, strengthening the genetic 
evidence (Table 1). Analysis of SNPs within SPATA13 showed that the second proband with 
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the 9 bp deletion is not related to Family 1. In this family the penetrance appears to be low, 
but we believe that the phenotype of the daughter is inherited from her mother, giving a 
penetrance of 100%. This is explained in detail in S3 text.  
 
Further evidence for the involvement of SPATA13 in PACG comes from the protein expression 
data shown in figure 5. This is the first study where SP-1277 expression is shown in iris, cornea, 
ciliary epithelium and retina of the human and murine eyes, the tissues most affected in 
PACG.  
 
A number of GWAS studies have implicated SP-1277 in several neurological disorders 
including intellectual disability [27], comorbid depression syndrome and alcohol dependence 
[28] and anorexia nervosa in human [29] and social hierarchy and nocturnal activity in mice 
[30]. It has also been implicated in differentiated thyroid cancer risk [31] and BRCA1-like early 
onset breast cancer [32]. The SPATA13 gene product has never been implicated in any eye 
disease, this is the first study implicating this protein in PACG. The gene produces several 
transcripts, here we have shown that two SPATA13 transcripts are ubiquitously present in cell 
lines derived from different human tissues as well as in the eye tissues including cornea, iris, 
retina, RPE and the lens. This raises an interesting question; if SPATA13 is a ubiquitously 
expressed protein, why do mutations in this gene only affect the eye? The obvious possibility 
is that the mutations do cause pathogenesis in other tissues, but they have not been 
diagnosed or investigated. It is also conceivable that in other organs the effect of mutations 
is overcome by tissue-specific expression of other proteins. However, there are reports where 
mutations in a ubiquitously expressed protein only affects the eye, e.g., mutations in PRPF31 
only cause retinitis pigmentosa and does not affect any other part of the body [33].  
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The SP-652 isoform has been reported to regulate cellular events such as reorganisation of 
cytoskeletal structures, cell migration [23] and angiogenesis [34, 35]. The other isoform SP-
1277 which has an additional 625 residues at the N-terminus due to alternative splicing of SP-
652, has never been investigated and its function is not known. SP-652 contains an 
adenomatous polyposis coli (APC)-binding region (ABR) followed by a Src homology 3 (SH3) 
domain, a Dbl homology (DH) domain and a Pleckstrin (PH) domain (Fig. 5A), which is also 
present in SP-1277. The ABR-SH3 domain binds to APC, which activates its GEF activity to 
mediate downstream cellular events [18]. At the protein level we show that endogenous SP-
1277 localises to both nucleus and cytoplasm in interphase, which is consistent with previous 
reports for endogenous SP-652 expression [36]. In silico 3-D structural prediction analysis 
showed that SP-1277 contains 16 intrinsically disordered regions (IDR) (Fig 3C), the longest of 
which is 157 residues. It has been reported that SP-652 is normally in an inactive conformation 
until the Armadillo (ARM) domain of APC binds to the ABR and SH3 domain and facilitate the 
Cdc42 exchange [26]. It is likely that post translational modification or binding of APC to the 
ABR-SH3 domain of SP-1277 releases the DH domain activating its GEF activity and that the 
IDR acquires a tertiary structure creating binding sites for other proteins and/or DNA/RNA for 
its additional downstream functions. SP-652 lacks this IDR and therefore binding of APC will 
result in downstream functions different to SP-1277. The 9 bp deletion (p.478_480del) is 
predicted to make the IDRs more compact (compare Figs. 3D with 3E), which would likely 
affect their interactions with binding proteins including APC. 
 
In this study we have shown dramatic redistribution of SP-1277 during different stages of cell 
division suggesting a role in mitosis. Although there are fundamental anatomical and 
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structural differences between the mouse and human eyes, such as lack of a lamina cribrosa 
or a macula, which may lead to different neurodegenerative pathways, two independent 
studies have shown that complete knockout of all SPATA13 isoforms in mouse was not 
embryonic lethal and had no ocular phenotype [30, 34]. This suggests that SPATA13 was not 
essential for mitosis, but instead may have a regulatory role. Similar results have been 
reported with myocilin (MYOC), a gene associated with POAG pathogenesis [37]. 
Heterozygous and homozygous mice lacking myocilin show no ocular phenotype, however, 
missense mutations in this protein are not tolerated and lead to POAG [38].  
 
Rho GTPases are involved in major cellular functions including cell growth, adhesion, motility, 
polarity and differentiation by controlling different cellular processes such as cytoskeletal 
remodeling, microtubule dynamics, gene transcription and phospholipid metabolism. Rho 
signaling responses in cells are highly regulated spatiotemporally to ensure homeostasis 
within the cell. They switch between active GTP bound and inactive GDP bound states with 
the help of RHO-GEFs, RHO-GAPs and RHO-guanine nucleotide dissociation inhibitors (RHO-
GDIs). The localised modulation of Rho GTPases by GEFs, GAPs and GDIs depends on cell type 
and presents a complex network of highly integrated regulatory mechanisms. Rho GTPases 
are also key components of neuronal cell degeneration pathways [39]. The Rho GTPase 
signaling pathway has been shown to modulate aqueous humour outflow by regulating the 
contractile properties of trabecular meshwork and Schlemm’s canal cells in humans [40, 41]. 
Inactivation of Rho GTPases significantly stimulated/increased adult ciliary epithelial cell 
proliferation in situ [42]. One of the key features of RHO-GEFs and RHO-GAPs is that their 
activities are autoinhibited and are sensitive to local activation. SP-652 has been shown to be 
inactive for RHO-GEF and is activated by binding to APC. In this report we only investigated 4 
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of the 8 SPATA13 variants for their effect on GEF activity. We have shown that SP-1277 
exhibits less GEF activity than SP-652 and the 9bp deletion increases the RAC1-dependent 
GEF activity. This has also been observed for three additional variants identified in SPATA13 
(Fig. 9), which suggested that conformational changes introduced by mutations in these 
variants affect the function through altering the GEF activity. It is likely that the rest of the 
variants that have not been tested might behave differently and may not show any difference 
in their GEF activity. It should be noted that PLEKHA7, another protein implicated in PACG 
(19), has GAP activity and therefore could interact with RAC1 similar to SP-1277. It is, 
therefore, also likely that both SP-1277 and PLEKHA7 are involved in Rho-GTPase pathway, 
indicating this pathway could play an important role in PACG disease pathogenesis. 
 
It is important to note that a proportion of SP-1277 is always in the cytoplasm even in dividing 
cells suggesting that it can also play a role in cell adhesion and migration. The mutations 
reported here enhance GEF activity of SP-1277, which could dysregulate mitosis with impact 
on symmetric/asymmetric cell division, cell adhesion and migration as has been reported for 
SP-652 [19, 21, 23, 43, 44]. Dysfunction in cell adhesion has been identified as a genetically 
modulated risk factor in PACG (14-19) and is likely to cause its effect through degradation of 
the blood aqueous barrier. PLEKHA7 encodes an apical junctional protein that is expressed in 
the non-pigmented ciliary epithelium, a key component of the blood aqueous barrier (BAB). 
Lee et al found that PLEKHA7 is down regulated in the iris of PACG patients that carry the C 
risk allele at SNP 11024102[13]. Silencing of PLEKHA7 in non-pigmented ciliary epithelium 
(NPCE) affected actin cytoskeleton organization in vitro. Consistent with the regulatory role 
of RAC-1 and Cdc42 in maintaining tight junction permeability, silencing of PLEKHA7 
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compromises the paracellular barrier between NPCE cells in vitro. The authors concluded that 
downregulation of PLEKHA7 in PACG may affect BAB integrity [13].  
 
Other evidence supporting the involvement of SPATA13 in PACG comes from our expression 
studies where it is highly expressed in iris, cornea, ciliary body and retina (Fig. 5C-F), the tissue 
most affected by the disease. The malformation of the ciliary epithelium would also impact 
aqueous humour secretion as well as attachment of lens zonules which would affect the 
positioning of the lens as observed in PACG [45]. Disturbances in tissue homeostasis of the 
uvea may increase the propensity for shedding of pigment from the pigmented ciliary or iris 
epithelia. We observed increased trabecular meshwork pigmentation in all patients carrying 
the 9 bp deletion, except the youngest two males aged 24y and 26y, in whom disease signs 
might develop later. 
 
APC and the kinetochore associated proteins have been investigated as targets for developing 
therapeutics for cancer treatment [46]. APC, which interacts with the two close homologues, 
ASEF1 and ASEF2 (41), is a peptidomimetic target for colon cancer treatment [47]. Cell cycle 
inhibitors are being investigated in targeting preferentially aneuploid cancer cells while 
sparing normal diploid cells. Similar strategies may offer the prospect of treatment for PACG 
involving APC-SPATA13/ASEF2 interactions.  
 
In conclusion, we have identified SPATA13 as a gene in which mutations cause primary angle-
closure disease, which in turn puts those affected at risk of developing glaucomatous loss of 
vision. There is variable expression and incomplete penetrance of the phenotype associated 
with this gene. Detailed functional characterisation of SP-1277 and mutations identified in 
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this study will provide insights into the mechanism of disease pathogenesis, strengthening 
the hypothesis that abnormalities in cell division and/or cell adhesion in the anterior segment 
of the eye might be a common mechanism in the development of PACG. Identification of 
SPATA13 as one of the disease-causing genes for PACG opens new avenues for identifying 
additional genes in this pathway causing PACG. 
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Methods and Materials 
 
Informed, written consent was obtained from all participants. This study followed the 
principles of the Declaration of Helsinki. The study was approved by the Moorfields NHS 
Research Ethics Committee (06/Q0504/8). 
 
Family history and pedigree recruitment  
The index patient for each family (proband), underwent pedigree charting, enquiring about a 
family history of glaucoma and/or angle-closure. The accuracy of family history information 
was confirmed by corroboration of relatives attending the clinics. All family members of the 
proband, aged 20 years and older were invited to attend ophthalmic examinations. The 
Society of Genealogists (http://www.sog.org.uk/) helped identify distant relatives using 
publicly available genealogy and census data. A family member from of the five largest 
families sent letters of invitation explaining the research to their distant relatives, inviting 
them to participate.  
 
Clinical examination 
Detail clinical examination procedure and diagnostic classification is given in S2 Text. Each 
participant examined in research clinics underwent comprehensive ophthalmic examination 
including dark room gonioscopy, visual field testing as well as a clinical examination of the 
optic disc, and supplementary imaging of the optic disc and peripapillary retina. The primary 
defining feature of cases was contact between the iris and trabecular meshwork identified on 
dark room gonioscopy and/or anterior segment imaging. Primary angle-closure glaucoma was 
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diagnosed when there was evidence of iridotrabecular contact and glaucomatous damage to 
the optic nerve, as detailed under the ISGEO diagnostic standards [2]. 
 
DNA isolation and Sanger sequencing 
DNA was extracted from peripheral blood using Gentra PureGene kit (Qiagen, UK). Sanger 
sequencing was performed with BigDyev3.1 (Life Technologies) on ABI3730 according to 
manufacturer’s protocol. 192 human random control DNAs were purchased from Merk. 
 
SNP chip array and linkage analysis 
Single nucleotide polymorphism (SNP) genotyping was undertaken on 11 individuals from 
Family I. Processing of SNP microarrays (Illumina, Human CytoSNP-12, 298,199 markers) was 
performed according to the manufacturer's protocol. The relationship status of participants 
was checked against their genotype using the GRR software 
(http://csg.sph.umich.edu/abecasis/grr/) to identify errors in pedigree charting and possible 
non-paternity. Overall call rates were >98% for all samples and no gender mismatch was 
found. The marker sets were reduced to the 3,547 most informative markers distributed 
uniformly throughout the chromosomes to avoid artificially inflating LOD scores due to 
linkage disequilibrium between closely spaced SNPs. All genotype calls were checked for 
Mendelian inconsistencies and two-point and multipoint linkage analyses of genome wide 
SNP data were performed using Superlink-Online SNP-1.1 [48] using an autosomal dominant 
model, 100% penetrance in the affected-only analysis, 90% penetrance in other analyses. 
 
Exome and whole genome sequencing 
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Genomic DNA from the proband of family I was fragmented enriched for exomic sequences 
using the Agilent SureSelect Whole Exome hybrid capture (Agilent, UK). The resulting enriched 
sequence library was sequenced with 76bp paired end reads across two lanes of Illumina 
GAIIx flowcell (v2 chemistry). The sequence reads were aligned to the reference genome 
(hg18) with the Novoalign aligner. Duplicate reads, resulting from PCR clonality or optical 
duplicates, and reads mapping to multiple locations were excluded from downstream 
analysis. Single nucleotide substitutions and small insertion/deletions were identified, and 
quality filtered within the SamTools software package. 
 
Whole genome sequencing was performed on HiSeqX with 30x coverage at Edinburgh 
Genomic Centre, UK. The sequence reads were aligned to hg19 and the data was obtained as 
BAM and VCF files. VCFTools were used to filter the variants within the genetically linked 
region. Pathogenicity of the variants were evaluated by VEF (Ensemble) and CADD. 
 
Antibodies 
Two SPATA13 antibodies, SP-1277 (ab122627) and SP-652 (ab122701) were purchased from 
Abcam (UK), PA5-59479, PA5-59096 from Thermofisher antibodies, PLK-1 (ab17057) and 
CENP-E (ab5093) from Abcam. Mouse monoclonal alpha-tubulin antibody (ab7291), were 
purchased from Abcam (UK). Alexa Fluor 488-conjugated goat anti-mouse (A11001) and anti-
rabbit (A11008) antibodies, Alexa Fluor 594-conjugated goat anti-mouse (A11005) and anti-
rabbit (A11034) antibodies, and donkey anti-goat antibodies conjugated with Alexa Fluor 488 
(A11055) and with Alexa Fluor 594 (A11058), were purchased from Life Technologies (CA, 
USA). Alexa Fluor 594 labelled Phalloidin was purchased from Life Technologies (CA, USA). 
Deleted:  ®
Deleted: ® 
Deleted: ® 
Deleted:  ®
Deleted:  ®
 27 
Horseradish peroxidase-conjugated goat anti-rabbit and anti-mouse IgG were purchased 
from Jackson Immuno Research Laboratories, Inc. (PA, USA). 
 
Molecular cloning and mutagenesis 
Total mRNA was isolated from cultured cells using the Dynabeads mRNA DIRECT Purification 
Kit (Ambion, Paisley, UK) using manufacturer’s instructions and transcribed into cDNA using 
the Transcriptor Reverse Transcriptase System (Roche, Burgess Hill, UK). The coding regions 
of SP-652 and SP-1277 were amplified using high fidelity Q5 DNA polymerase (New England 
Biolabs, UK) and ligated into pLPC_NAcGFP using standard cloning techniques [49]. The 
retroviral expression vector pLPC_NMyc (gift from Professor Titia de Lange (Addgene plasmid 
#12540) was re-engineered to replace N-Myc tag with AcGFP. For site-directed mutagenesis 
phosphorylated primers harbouring the desired mutations were used to amplify the SPATA13 
constructs with Q5 DNA polymerase and ligated with Taq DNA ligase. Sanger sequencing was 
used to verify all cloned inserts and mutations. 
 
SDS electrophoresis and western blotting 
SDS electrophoresis and western blotting were performed according to protocol described 
previously [50]. 
 
mRNA extraction, cDNA synthesis and quantitative PCR 
Total RNAs from pooled human eye tissues, ciliary body, iris, retinal epithelium and retina 
were commercially obtained from 3H Biomedical AB (Sweden) and isolated from cornea and 
lens tissues using RNeasy Mini Kit (Qiagen) as per manufacturer’s instructions. The RNA 
samples were reverse transcribed into cDNAs as described above. Specific primers for three 
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different forms of SPATA13 (NM_001286792; NM_001166271 and NM_153023; were 
designed spanning exon-exon junctions with Tm of forward and reverse primers within ±1oC. 
NM_001286792; F: AAGGACCCTCTGAGGACGTAG; R: ACAGGTCACCCCTAGCTGG, 
NM_001166271; F: ACGCTGACTTTGTAGGCTCC; R: TCATCTCCAGGAATGCCGTC, NM_153023; 
F: GACACGCTGACTTTGTAGGC; R: ATCCTGTGATGAGCTTCGCC, SPATA13_Total; F: 
GCTCAAAAGGCAGGACATGG; R: CATAGTGATGTGGCGCTGGT. Quantitative PCR (qPCR) was 
performed on the LightCycler 480 qPCR System (Roche, UK) according to protocol described 
by Bose et al. [51]. The qPCR analyses for mRNA expression in cell lines were performed in 
three independent replicates, with three technical repeats for every sample. However, for 
human eye tissues the expression was performed only in three technical replicates. 
  
Mammalian Cell Culture and Immunocytochemistry 
Human (h)TERT-RPE-1 retinal pigment epithelial cell line was maintained in Dulbecco's 
modified Eagle's medium (DMEM)/F-12+GlutaMAX (Life Technologies, CA, USA) 
supplemented with 10% FCS and penicillin–streptomycin (100 µg/ml). All cells were grown in 
6-well plates at 1.2 x106 cells per well at 37°C in an atmosphere of 5% CO2. 
 
Prior to immunofluorescence (IF) studies, cells were seeded in 24-well plates on glass 
coverslips at 5.0 x 104 cells per well and incubated for 24 h. The cells were processed for 
immunocytochemistry as described previously [50].  
 
Transfections were performed in semi-confluent hTERT-RPE1 or HT1080 cells using the 
TransIT-LT1 Transfection Reagent (Mirus Bio LLC, USA), according to the manufacturer’s 
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instructions. The cells were fixed 24 h post transfection prior to IF staining as described above. 
Retroviral packaging and transduction was carried as described previously [50] 
 
Imaging and image processing 
Confocal images were obtained on Zeiss LSM880 with a 63x/1.4NA oil objective.  Quantitation 
of colocolisation is described in S5 Text. 
 
GEF activity measurement:  
RPE-1 cells were co-transfected with wildtype SP-1277 or mutants (S292I, S473N, 478-480del, 
P964L) or wildtype SP-652 or SP-652(P964L) or SP-652del204 cloned in pLPCpuro_NAcGFP 
along with Flag-RAC-1 using TransIT-LT1 Transfection Reagent (Mirus Bio LLC, USA), according 
to the manufacturer’s instructions. After 24 h the transfected cells were starved in 0.5% 
serum for 4 h. The cells were lysed, GTP-RAC-1 was pulled down using PAK-PBD beads 
(Cytoskeleton incorporation, USA) and analysed on 4-15% gradient gel followed by western 
blot using anti-Flag antibody. The blots were analysed and quantified by ChemiDoc using 
Image Lab software from Bio-Rad.  
 
Immunohistochemistry 
Formalin fixed paraffin embedded human eye tissues and murine eye were cut into 5µm 
sections, dewaxed using xylene and immunostained using SP-1277 N-terminus specific 
antibody as described previously [52, 53]. 
 
3D structure prediction 
I-TASSER was used for prediction of secondary and tertiary structure of SPATA13 [54]. 
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Statistical analysis: Gene expression data were exported from Roche LightCycler LC480 
Software as text files for subsequent analysis. Statistical analysis for qPCR and GEF assays 
were carried out by the t-test on Graph Pad Prism software and Microsoft Excel.  
 
URLs used in the study 
http://www.ensembl.org/index.html 
http://csg.sph.umich.edu/abecasis/grr/ 
http://cbl-hap.cs.technion.ac.il/superlink-snp/ 
https://zhanglab.ccmb.med.umich.edu/I-TASSER/ 
http://cadd.gs.washington.edu/ 
http://www.sog.org.uk/ 
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Supporting information legends 
S1 Text: Selection criteria for Family 1 
 
S2 Text: Clinical examination & Diagnostic Classification 
 
S3 Text: SNP analysis and clinical details of family 5:II 
 
S4 Text: Pathogenicity of variants 
 
S5 Text: Co-localisation analysis of SP-1277 with the kinetochore markers, PLK-1 and CENPE 
 
S6 Text: Variable expression and incomplete penetrance in Family 1 
 
S1 Fig: Overexpression of mutant SPATA13-FL protein tagged with AcGFP. RPE-1 cells were 
transiently transfected with mutant AcGFP-tagged SPATA13 constructs, and co-stained using 
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anti-SC35 antibody, a marker for nuclear speckles. Mutations are as follows: (A) SP-1277-
S292I; (B) SP-1277-S473N; (C) SP-1277-9bp del; (D) SP-1277-P964L; and (E) SP-652-P964L. 
Mutant proteins did not show co-localisation with SC35. Nuclei were stained using DAPI (blue).  
 
S1 Table: Detailed clinical information of members in Family 1.  
 
S2 Table: Genotypes of eight affected and two unaffected subjects of Family 1. 
 
S3 Table: Detailed clinical information of 8 additional PAC/PACG patients and their relatives 
carrying mutations in SPATA13.  
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Figure legends 
Figure 1: Pedigree of Family 1. The proband is V:8 (red arrow) and this pedigree shows the 
relationship of the 62 individuals examined (see S1 Table for detailed phenotype). There was 
no male-to-male transmission observed, and the only affected male was V:30, a first cousin 
of the proband. From branch B, two out of nine individuals examined were affected. There 
were no individuals examined from branches A and C affected with angle-closure disease. 
Twelve subjects, four of whom were affected first cousins, were genotyped for genetic linkage 
analysis, and some were analysed in greater detail by exome and whole genome sequencing. 
It is suspected that the phenotype in VII:2 and VI:7 is caused by another genetic defect as it is 
very likely that their disease is inherited from the married in spouse (V:11). 
 
Figure 2: Clinical features and linkage analysis of Family 1. (A) Plateau iris configuration was 
observed for all nine clearly affected individuals V:8, V:15, VI:4, V:32, V:30, IV:27, VI:12 and 
V:34, V:41) on gonioscopy. In the first two columns, closed anterior chamber drainage angles 
are observed. The middle column shows high resolution AS-OCT angle imaging, where the 
bulky ciliary body typical of plateau iris is observed. Individual IV:27 is the oldest and most 
severely affected PACG individual, showing some additional iris convexity. Individuals V:28, 
VI:36 and VI:6 have open drainage angles and are shown for comparison. (B) Maximum 
multipoint LOD score of 3.5 achieved at chromosome 13 by Superlink-Online SNP-1.1. (C) 
Pedigree of the family 5 identified with the 9 bp deletion. The proband, 5.II.2, shown by an 
arrowhead carry the deletion. His mother, 5.I.2 was affected but no DNA was available for 
analysis. Proband has an affected daughter, 5.III.2, but her eye phenotype is different to his. 
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Her mother, 5:II.3, has narrow but open angles and was hyperopic and it is therefore 
suspected that the daughter has inherited her disease from the mother.  
 
Figure 3: Location and predicted effect of mutations in SPATA13 gene on protein 
conformation. (A) Structure of SPATA13 gene structure and location of 8 mutations in exon 2 
and the 9th mutation in exon 9. (B) Conservation of amino acids mutated in PACG in 9 different 
species. (C) Secondary structure prediction for the amino acid sequence of SPATA13 
polypeptide. (D) Predicted tertiary structure of SP-1277 containing the 9bp (p. 478-480del) 
deletion. (E) Wildtype SP-1277 showing the location of all the missense variants. 
 
Figure 4: Expression of different SPATA13 transcripts in human cell lines and eye tissues. (A) 
Schematic representation of the transcripts of different isoforms of SPATA13. The two isoform 
SP-1277 and SP-652 isoforms are generated by alternative splicing of exons toward the N-
terminal. The position of qPCR primers used to differentiate the 2 transcripts are also shown. 
(B) Expression of SPATA13 transcripts by qPCR in 17 different cell lines derived from human 
eye, breast, liver, skin, head and neck, cervix and kidney. (C) Expression of SP-1277 and SP-652 
transcripts in human iris, ciliary epithelium, retinal pigment epithelium, retina, cornea and 
lens. The green bars represent SPATA13-Total whereas the blue bars represent SP-1277 and 
the red bars represent SP-652. 
 
Figure 5: Characterisation of SP-1277 isoform. (A) Schematic representation of the domain 
structure of SP-1277 isoform. Light blue bar shows the epitope for the N-terminal antibodies 
and the red bar shows epitope for the C-terminal antibodies. The nuclear localisation signal 
in the terminal region SP-1277N625is shown by a hashed blue bar. The boundary of SP-1277-
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N625 and SP-652 are shown two discontinuous lines. The SH3, DBL homology (DH) and PH 
domains are shown in SP-652. (B) Western blot analysis of the SPATA13 and its fragments 
analysed by N-terminus (ab122627) and anti-AcGFP antibodies. AcGFP fusion protein of SP-
1277, SP-1277-N625 and the SP-652 were expressed in HT1080 cells, total cell lysate was 
separated on 4-15% SDS polyacrylamide gel, transferred on nitrocellulose membrane and 
probed with different antibodies. Specific reactivity with protein bands is shown by asterisks. 
(C) Western blot of total RPE-1 lysate probed with the C-terminus (lane 1) and N-terminal 
(lane 2, ThermoFisher; lane 3, Abcam) antibodies. (D) Reactivity of N- and C-terminal 
antibodies with RPE-1 cells overexpressing SP-1277 compared with AcGFP control. 
Immuohistochemical reactivity of murine eye tissues (E, F) and human eye tissues (G) with 
the N-terminus antibody from Abcam (ab122627). CE= ciliary epithelium, CP=ciliary process, 
PP=pars plana, GCL= ganglion cell layer, INL= inner nuclear layer, ONL= outer nuclear layer, 
SM=sphincter muscle, DM= dilator muscle, PE= posterior muscle. Re= retina, Co=cornea, Le= 
lens. 
 
Figure 6: Endogenous and ectopic expression of SPATA13 isoforms. Human RPE-1 cells were 
immunostained with SP-1277 (N-terminus antibody, A) and SP-652 (C-terminus antibody, B) 
and co-stained for endogenous F-actin (Alexa Fluor 594 conjugated phalloidin). (C) To detect 
nuclear actin, RPE-1 cells were transfected with nuclear actin chromobody (nAC) probe 
construct [55] and were counterstained with N-terminal specific SP-1277 antibody. RPE-1 cells 
were transiently transfected with AcGFP-tagged SP-1277 (D), and SP-1277-N625(E) 
respectively, both counterstained for F-actin. AcGFP-SP-1277 localised to nuclear speckles 
with a diffuse but variable cytoplasmic signal (S), AcGFP-SPATA13-N625 (E) only showed nuclear 
staining. Nuclei were stained with DAPI (blue). Scale bar = 10 µM. 
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Figure 7: Endogenous SP-1277 isoform during mitosis. Endogenous SP-1277 protein was 
localised in dividing RPE-1 cells, during mitosis using the N-terminus antibody and 
counterstained using anti-acetylated ⍺-tubulin antibody (A), or counter stained with two 
mitotic markers PLK-1 (B) and CENP-E (C). (A) SP-1277 was detected in the nucleus as speckles 
at G0, which intensified at the onset of prophase, aligning along the kinetochore at 
metaphase, and anaphase, before returning to its G0 localisation pattern. (B) SP-1277 globules 
show co-localisation with the kinetochore marker PLK-1 at prophase, metaphase and 
anaphase. At cytokinesis the PLK-1 staining is primarily localized at midbody between the 
dividing cell which also co-stains for SP-1277. (C) SP-1277 show strong co-localisation with 
another kinetochore marker CENP-E at prophase, prometaphase and anaphase. At anaphase 
the colocalization primarily is around the separated chromosomes. Nuclei were stained using 
DAPI (blue).  
 
Figure 8: Colocalization analysis of SP-1277 with CENP-E at prometaphase and anaphase. 
(A) At prometaphase SP-1277 (green) co-localises with CENPE-E (red) globules. To evaluate 
whether colocalization occurs, a line was drawn connecting different globules (B). The green 
and red intensity was measured using ImageJ in globules along the line and plotted (C). The 
data was analysed using Image J and Imaris softwares and showed colocalization of 84% 
(tM0.84) of CENP-E with SP-1277 and 75% (tM=0.75) of SP-1277 with CENP-E. Fluorescence 
intensity data of two images were distributed linearly as shown in the scatterplots (Fig. 8D & 
8E). The colocalization of SP-1277 with CENP-E in anaphase is shown in (F). The regions of 
interest showing highest colocalization are labelled as 1 and 2. The degree of colocalization 
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of the two molecules was analysed using ImageJ (1a, and 1b for region 1) and (2a and 2b for 
region 2) and gave a colocalization of more than 80%. 
 
Figure 9: SPATA13 mutations induced GEF activity in SP-1277. (A) RPE-1 cells were co-
transfected with Flag-RAC-1 along with wildtype SP-1277, wildtype SP-652 or mutants (S292I, 
S473N, 478-480d, P964L) cloned in pLPCpuro_NAcGFP and after lysis the GTP-RAC-1 was 
immunoprecipitated with PAK-PBD beads and analysed on western blot using anti-Flag 
antibody. (B) Quantification of GEF activity of SP-1277 (wildtype and mutants). One way 
ANOVA was used to test the null hypothesis of no difference between GEF activity in mutants 
and wildtype, with there being a significant difference (p=0.002). 
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Table 1: List of variants identified in SPATA13 in a cohort of 189 PAC/PACG patients.  
 
patient 
ID 
Location CDS 
position 
Protein 
position 
SIFT PolyPhen CADD 
score 
gnomAD 
Allele 
Frequency 
6:I 13:24223195-
24223195 
c.G266C p.R89P deleterious Probably 
damaging 
26.5 0.001335 
7:I 13:24223426-
24223426 
c.C497T p.P166L tolerated benign 9.475 0.001762 
8:I 13:24223666-
24223666 
c.G737C p.S246T tolerated benign 12.47 0.0000381 
4:I 13:24223804-
24223804 
c.G875T p.S292I tolerated possibly 
damaging 
22.3 0.00000661 
10:I 13:24224016-
24224016 
c.C1087T p.R363C deleterious Possibly 
damaging 
25.5 0.0002 
9:I 13:24224083-
24224083 
c.C1154T p.A385V tolerated benign 15.17 0.00115 
2:II:I 13:24224347-
24224347 
c.G1418A p.S473N deleterious Possibly 
damaging 
22.4 0.000824 
3:I 13:24290695-
24290695 
c.C2891T p.P964L tolerated Probably 
damaging 
24.9 0.0000244 
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